Outcome of Radiation Therapy in Operated Gastric Cancer
Outcome of Radiation Therapy In Operated Gastric Cancer
1 other identifier
observational
40
0 countries
N/A
Brief Summary
- Study tolerability and toxicity of radiotherapy with or without chemotherapy for operated gastric cancer.
- Evaluate the efficacy of adjuvant radiotherapy with or without chemotherapy as regarding local control and overall survival.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2021
CompletedFirst Posted
Study publicly available on registry
March 23, 2021
CompletedStudy Start
First participant enrolled
April 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2023
CompletedMarch 23, 2021
March 1, 2021
1.8 years
March 8, 2021
March 21, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy of Radiotherapy in operated gastric cancer
Disease Free Survival
Baseline
Interventions
Adjuvant Radiotherapy in operated gastric cancer
Eligibility Criteria
Age of the patient; ≥18 and ≤75 years. Histologically proven gastric or gastroesophageal adenocarcinoma. Pt received adjuvant Radiotherapy with or without chemotherapy with any protocol.
You may qualify if:
- Age of the patient; ≥18 and ≤75 years.
- Histologically proven gastric or gastroesophageal adenocarcinoma.
- Pt received adjuvant Radiotherapy with or without chemotherapy with any protocol.
You may not qualify if:
- Patient \>75 years\&\<18 years.
- Histologically types other than adenocarcinoma .
- Metastatic patients (M1).
- Pt didn't recive radiotherapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
1- A. Schernberg,a E. Rivin del Campo,a B. Rousseau,b O. Matzinger,c M. Loi,d P. Maingon,e,f and F. Hugue. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. ClinTranslRadiatOncol. 2018 Mar 13: 13-22. 2- Karimi P., Islami F., Anandasabapathy S., Freedman N.D., Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-713. 3- Forman D., Burley V.J. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res ClinGastroenterol. 2006;20(4):633-649. 4- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [Internet]. [cited 2014 Feb 22]. Available from: <http://globocan.iarc.fr/Pages/references.aspx>. 5- Ministry of Health and Population. Gharbiah Population Based Cancer Registry, Egypt. .Cancer in Egypt, triennial report of 2000-2002. 2007. MOH: Tanta, Egypt. 6-Alieldin N. NCI hospital-based registry 2002-2010 [Internet]. [cited 2014 Feb23].Availablefrom:<http://nci.cu.edu.eg/App_Files/registry/NCI_registry%202002-2010.pdf>. 7-Freedman L, Edwards B, Ries L, Young J, editors. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. National Cancer Institute, 2006. NIH Pub. No. 06-5873. Bethesda, MD [Internet]. [cited 2014 Feb 22]. 8- Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through upregulation of bax and bak. Carcinogenesis. 2001;22:1393-97 9-Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of helicobacter pylori infection combined with cagA and pepsinogen status on gastric cancer development among Japanese men and women: A nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2006;15:1341-47. 10- Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H, et al. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res. 1996;87:1263-70. 11-Buckland G, Travier N, Huerta JM, et al. Healthy lifestyle index and risk of gastric adenocarcinomaintheEPIC cohort study.IntJ Cancer. 2015;137(3):598-606. 12-Massarrat S, Stolte M. Development of gastric cancer and its prevention. Arch Iran Med. 2014;17(7):514-520. 13-Zhang ZX, ,Gu XZ, , Yin WB, , Huang GJ, , Zhang DW, , Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J RadiatOncolBiolPhys 1998; 42: 929-34. 14- Macdonald JS, , Smalley SR, , Benedetti J, , Hundahl SA, , Estes NC, , Stemmermann GN, et al. . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30. 15- M Fan W Hu Z Zhang. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol July 2015; ( 88(1051).
RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal Investigator
Study Record Dates
First Submitted
March 8, 2021
First Posted
March 23, 2021
Study Start
April 1, 2021
Primary Completion
January 1, 2023
Study Completion
April 1, 2023
Last Updated
March 23, 2021
Record last verified: 2021-03